NCT03920618

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

Study on Three Types of Nucleotide/Nucleoside Analogues Treatment in Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Third Affiliated Hospital, Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 12 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

Detailed description

Hepatitis b virus (HBV) related acute-on-chronic liver failure (ACLF) is a serious condition with high mortality rate in China. Nucleotide/nucleoside analogues are used for anti-virus treatment in these patients. Entecavir, Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide are first line drug in China. But there still lacks of data of Tenofovir Alafenamide in treatment of HBV related ACLF. This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV related ACLF.

Conditions

• Hepatitis B
• Acute-On-Chronic Liver Failure

Interventions

Type	Name	Description
DRUG	Entecavir	Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
DRUG	Tenofovir Disoproxil Fumarate	Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
DRUG	Tenofovir Alafenamide	Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.

Timeline

• Start date: 2019-02-21
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2019-04-19
• Last updated: 2024-11-29

Locations

1 site across 1 country: China